Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update).
作者信息
Levine M
机构信息
Cancer Care Ontario Hamilton Regional Cancer Centre, Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont.
出版信息
CMAJ. 2001 Jan 23;164(2):213.
Abstract
摘要
相似文献
1
2
Chemotherapy for older women with node-positive breast cancer.
CMAJ. 2001 Sep 4;165(5):525, 527.
3
Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
J Natl Cancer Inst Monogr. 2006(36):7-15. doi: 10.1093/jncimonographs/lgj003.
4
5
[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Ugeskr Laeger. 2007 Jan 22;169(4):297-9.
6
Estimating the benefits of adjuvant systemic therapy for women with early breast cancer.
Br J Surg. 2001 Nov;88(11):1513-8. doi: 10.1046/j.0007-1323.2001.01902.x.
7
Systemic adjuvant therapy for breast cancer.
Nebr Med J. 1996 Mar;81(3):48-50.
8
The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
Clin Adv Hematol Oncol. 2008 Aug;6(8):573-4.
9
Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Eur J Cancer. 2007 Jan;43(2):331-40. doi: 10.1016/j.ejca.2006.10.009. Epub 2006 Nov 28.
10
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
J Clin Oncol. 2006 Mar 20;24(9):1332-41. doi: 10.1200/JCO.2005.03.0783. Epub 2006 Feb 27.
引用本文的文献
1
PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease.
JNCI Cancer Spectr. 2019 Aug 29;4(1):pkz063. doi: 10.1093/jncics/pkz063. eCollection 2020 Feb.
2
Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.
J Clin Oncol. 2011 Jul 20;29(21):2852-8. doi: 10.1200/JCO.2010.33.4714. Epub 2011 Jun 13.
3
A model building exercise of mortality risk for Taiwanese women with breast cancer.
BMC Med Inform Decis Mak. 2010 Aug 19;10:43. doi: 10.1186/1472-6947-10-43.
4
The role of aromatase inhibitors in early breast cancer.
Curr Treat Options Oncol. 2003 Apr;4(2):133-40. doi: 10.1007/s11864-003-0014-y.
5
Tamoxifen for breast cancer prevention: safety warning.
CMAJ. 2002 Aug 20;167(4):378-9.
6
Keeping breast cancer guidelines current.
CMAJ. 2001 Jan 23;164(2):212.
本文引用的文献
1
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet. 1998 Sep 19;352(9132):930-42.
2
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet. 1998 May 16;351(9114):1451-67.
Zotero 插件